Randomized Controlled Trial
. 2016 Jan;111(1):105-14. doi: 10.1038/ajg.2015.367. Epub 2015 Nov 3. Adherence to Competing Strategies for Colorectal Cancer Screening Over 3 YearsAffiliations
AffiliationsItem in Clipboard
Randomized Controlled Trial
Adherence to Competing Strategies for Colorectal Cancer Screening Over 3 YearsPeter S Liang et al. Am J Gastroenterol. 2016 Jan.
. 2016 Jan;111(1):105-14. doi: 10.1038/ajg.2015.367. Epub 2015 Nov 3. AffiliationsItem in Clipboard
AbstractObjectives: We have shown that, in a randomized trial comparing adherence to different colorectal cancer (CRC) screening strategies, participants assigned to either fecal occult blood testing (FOBT) or given a choice between FOBT and colonoscopy had significantly higher adherence than those assigned to colonoscopy during the first year. However, how adherence to screening changes over time is unknown.
Methods: In this trial, 997 participants were cluster randomized to one of the three screening strategies: (i) FOBT, (ii) colonoscopy, or (iii) a choice between FOBT and colonoscopy. Research assistants helped participants to complete testing only in the first year. Adherence to screening was defined as completion of three FOBT cards in each of 3 years after enrollment or completion of colonoscopy within the first year of enrollment. The primary outcome was adherence to assigned strategy over 3 years. Additional outcomes included identification of sociodemographic factors associated with adherence.
Results: Participants assigned to annual FOBT completed screening at a significantly lower rate over 3 years (14%) than those assigned to colonoscopy (38%, P<0.001) or choice (42%, P<0.001); however, completion of any screening test fell precipitously, indicating the strong effect of patient navigation. In multivariable logistic regression analysis, being randomized to the choice or colonoscopy group, Chinese language, homosexuality, being married/partnered, and having a non-nurse practitioner primary care provider were independently associated with greater adherence to screening (P<0.01).
Conclusions: In a 3-year follow-up of a randomized trial comparing competing CRC screening strategies, participants offered a choice between FOBT and colonoscopy continued to have relatively high adherence, whereas adherence in the FOBT group fell significantly below that of the choice and colonoscopy groups. Patient navigation is crucial to achieving adherence to CRC screening, and FOBT is especially vulnerable because of the need for annual testing.
Conflict of interest statementConflict of Interest : Potential competing interests : None.
FiguresFigure 1
Study flowchart. Number of individuals…
Figure 1
Study flowchart. Number of individuals who completed the strategy is cumulative and indicates…
Figure 1Study flowchart. Number of individuals who completed the strategy is cumulative and indicates adherence to assigned group through the time of follow-up. Number of individuals who did not complete the strategy is non-cumulative and indicates data for one year.
Figure 2
Adherence to assigned colorectal cancer…
Figure 2
Adherence to assigned colorectal cancer screening strategy. Adherence in the choice group is…
Figure 2Adherence to assigned colorectal cancer screening strategy. Adherence in the choice group is shown in the third bar of each follow-up period.
Similar articlesInadomi JM, Vijan S, Janz NK, Fagerlin A, Thomas JP, Lin YV, Muñoz R, Lau C, Somsouk M, El-Nachef N, Hayward RA. Inadomi JM, et al. Arch Intern Med. 2012 Apr 9;172(7):575-82. doi: 10.1001/archinternmed.2012.332. Arch Intern Med. 2012. PMID: 22493463 Free PMC article. Clinical Trial.
Green BB, Anderson ML, Chubak J, Fuller S, Meenan RT, Vernon SW. Green BB, et al. Cancer. 2016 Jan 15;122(2):312-21. doi: 10.1002/cncr.29734. Epub 2015 Oct 21. Cancer. 2016. PMID: 26488332 Free PMC article. Clinical Trial.
You JJ, Liu Y, Kirby J, Vora P, Moayyedi P. You JJ, et al. Trials. 2015 Jul 9;16:296. doi: 10.1186/s13063-015-0826-7. Trials. 2015. PMID: 26156248 Free PMC article. Clinical Trial.
Quintero E. Quintero E. Gastroenterol Hepatol. 2009 Oct;32(8):565-76. doi: 10.1016/j.gastrohep.2009.01.179. Epub 2009 Jul 3. Gastroenterol Hepatol. 2009. PMID: 19577340 Review. Spanish.
Vernon SW. Vernon SW. J Natl Cancer Inst. 1997 Oct 1;89(19):1406-22. doi: 10.1093/jnci/89.19.1406. J Natl Cancer Inst. 1997. PMID: 9326910 Review.
Zauber AG, Winawer SJ, O'Brien MJ, Mills GM, Allen JI, Feld AD, Jordan PA, Fleisher M, Orlow I, Meester RGS, Lansdorp-Vogelaar I, Rutter CM, Knudsen AB, Mandelson M, Shaukat A, Mendelsohn RB, Hahn AI, Lobaugh SM, Soto Palmer B, Serrano V, Kumar JR, Fischer SE, Chen JC, Bayuga-Miller S, Kuk D, O'Connell K, Church TR. Zauber AG, et al. Gastroenterology. 2023 Jul;165(1):252-266. doi: 10.1053/j.gastro.2023.03.206. Epub 2023 Mar 21. Gastroenterology. 2023. PMID: 36948424 Free PMC article. Clinical Trial.
Hua H, Meydan C, Afshin EE, Lili LN, D'Adamo CR, Rickard N, Dudley JT, Price ND, Zhang B, Mason CE. Hua H, et al. Front Immunol. 2022 May 30;13:889702. doi: 10.3389/fimmu.2022.889702. eCollection 2022. Front Immunol. 2022. PMID: 35711426 Free PMC article.
Piscitello A, Saoud L, Fendrick AM, Borah BJ, Hassmiller Lich K, Matney M, Ozbay AB, Parton M, Limburg PJ. Piscitello A, et al. PLoS One. 2020 Dec 29;15(12):e0244431. doi: 10.1371/journal.pone.0244431. eCollection 2020. PLoS One. 2020. PMID: 33373409 Free PMC article.
Ahlquist DA. Ahlquist DA. Gastroenterol Hepatol (N Y). 2019 Aug;15(8):437-440. Gastroenterol Hepatol (N Y). 2019. PMID: 31592245 Free PMC article. No abstract available.
Tate CE, Matlock DD, Dalton AF, Schilling LM, Marcus A, Schommer T, Lyon C, Lewis CL. Tate CE, et al. Jt Comm J Qual Patient Saf. 2018 Jun;44(6):353-360. doi: 10.1016/j.jcjq.2017.11.009. Epub 2018 Apr 25. Jt Comm J Qual Patient Saf. 2018. PMID: 29793886 Free PMC article.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3